Mathias Schneeweiss
Overview
Explore the profile of Mathias Schneeweiss including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wewalka M, Schneeweiss M, Haselwanter P, Schneeweiss B, Zauner C
Nutrition
. 2022 Jun;
101:111684.
PMID: 35660504
Objectives: Resting energy expenditure (REE) declines with age in healthy individuals, independent of the age-related decrease in lean body mass. The aim of this study was to evaluate whether this...
2.
Gleixner K, Sadovnik I, Schneeweiss M, Eisenwort G, Byrgazov K, Stefanzl G, et al.
Leuk Res
. 2019 Feb;
78:36-44.
PMID: 30711891
In chronic myeloid leukemia (CML), resistance against second-generation tyrosine kinase inhibitors (TKI) remains a serious clinical challenge, especially in the context of multi-resistant BCR-ABL1 mutants, such as T315I. Treatment with...
3.
Schneeweiss M, Wewalka M, Zauner C
N Engl J Med
. 2019 Feb;
380(5):498.
PMID: 30702242
No abstract available.
4.
Wewalka M, Drolz A, Seeland B, Schneeweiss M, Schmid M, Schneeweiss B, et al.
Eur J Clin Nutr
. 2018 Aug;
73(1):158.
PMID: 30082845
After publication, the author noticed that Table 2 was incorrectly formatted for the final PDF despite being correct in earlier proofs. The table was correct in the HTML version of...
5.
Wewalka M, Drolz A, Seeland B, Schneeweiss M, Schmid M, Schneeweiss B, et al.
Eur J Clin Nutr
. 2018 Feb;
72(4):496-503.
PMID: 29459791
Background/objectives: Hyperglycemia is common in critically ill patients and associated with increased mortality. It has been suggested that different nutrition formulas may beneficially influence glucose levels in surgical intensive care...
6.
Schneeweiss M, Peter B, Bibi S, Eisenwort G, Smiljkovic D, Blatt K, et al.
Haematologica
. 2018 Feb;
103(5):799-809.
PMID: 29439183
Systemic mastocytosis is a complex disease defined by abnormal growth and accumulation of neoplastic mast cells in various organs. Most patients exhibit a D816V-mutated variant of , which confers resistance...
7.
Gleixner K, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, et al.
Haematologica
. 2017 Jun;
102(9):1519-1529.
PMID: 28596283
In chronic myeloid leukemia, resistance against BCR-ABL1 tyrosine kinase inhibitors can develop because of mutations, activation of additional pro-oncogenic pathways, and stem cell resistance. Drug combinations covering a broad range...
8.
Valent P, Herndlhofer S, Schneeweiss M, Boidol B, Ringler A, Kubicek S, et al.
Oncotarget
. 2017 Apr;
8(14):23061-23072.
PMID: 28416739
In chronic myeloid leukemia (CML) resistance against one or more BCR-ABL1 tyrosine kinase inhibitors (TKI) remains a clinical challenge. Preclinical data suggest that TKI combinations may overcome resistance. We report...
9.
Argeny S, Stift A, Mittlbock M, Lord A, Maschke S, Schneeweiss M, et al.
Int J Surg
. 2016 Aug;
33 Pt A:182-6.
PMID: 27535116
Purpose: Due to a lack of data, the present study was designed to assess the impact of advanced age on surgical characteristics and short-term outcome of patients operated on for...
10.
Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G, Stefanzl G, et al.
Blood
. 2015 Oct;
126(26):2832-41.
PMID: 26486787
The Ki-1 antigen (CD30) is an established therapeutic target in patients with Hodgkin lymphoma and anaplastic large-cell lymphoma. We have recently shown that CD30 is expressed abundantly in the cytoplasm...